Orange

Researchers are investigating how often adults from minority groups, specifically Black/African American and Hispanic/Latino individuals with refractory metastatic colorectal cancer, experience high blood pressure after treatment with fruquintinib. The study also aims to assess the safety and tolerability of fruquintinib in these populations. This phase 4 trial focuses on patients who have already undergone standard therapies but continue to have advanced disease. Participants will receive oral fruquintinib capsules in treatment cycles lasting four weeks each. They will continue the treatment until their condition worsens, they cannot tolerate the medication, or they choose to stop for other reasons. After completing the treatment phase, participants will be monitored every three months until the study ends. Throughout the study, participants will undergo regular health assessments to monitor blood pressure and evaluate any treatment-related side effects. Researchers will track the occurrence of severe hypertension from the first dose through approximately 35 months of follow-up. Additional safety evaluations and disease assessments will help determine how well participants tolerate fruquintinib and its effects on their cancer.